{{Subject}}
Real Chemistry’s weekly analysis of biopharmaceutical pricing and value news, provided free of charge.
Real Chemistry
Value Report
October 30, 2026
 
 
New DOL Rule Reveals PBM Compensation for the First Time

The Trump administration finalized a rule Thursday requiring PBMs to disclose fees, rebates, spread pricing and financial relationships with brokers and consultants to the self-insured employer plans that hire them.

This marks the first time U.S. employers will see the full range of payments flowing to their PBMs from drugmakers and other entities. The rule, issued under ERISA’s service provider prohibited transaction exemption, covers more than 70 PBMs and 130,000 employers, with disclosures required beginning July 1, 2027.

Labor Secretary Keith Sonderling framed it as a market competition measure, saying it ensures “no one in the healthcare industry can escape the competition that comes from complete price transparency.”

Federal officials project more than $800 million in annual savings for the over 72 million Americans on self-insured plans. That projection, offered without detailed methodology, assumes employers will act on the newly available data by renegotiating contracts or switching PBMs.

The PBM industry pushed back immediately. In a statement, PCMA President and CEO David Marin called the rule “a solution in search of a problem,” arguing that PBM transparency legislation enacted months ago already requires drug-by-drug, claim-by-claim disclosure. Marin warned it will produce “higher patient costs and less competition,” and PCMA has signaled it is weighing legal options.

The DOL rule was not the only pressure PBMs faced this week. House Oversight Committee Chair James Comer, R-Ky., sent letters to three major PBMs demanding documents related to audits of independent pharmacies. Separately, a bipartisan group of Senators called on the FTC to complete its four-year-old PBM investigation and deliver formal recommendations to Congress.

– Leslie Isenegger, Head of Policy, Public Affairs and Access, RC Resolve

U.S. COINS Rule Could Make Change for Chinese Vendors

Proposed federal limits on outbound biotech investment could have a chilling effect on partnerships between the U.S. and Chinese companies.

The proposed rule, published by the Treasury Department and shaped by the White House, would bar U.S. companies and investors from acquiring stakes in or forming joint ventures with select Chinese companies. The rule would apply to companies engaged in “the development, engineering, or use of a biological system” to make or modify pharmaceutical compounds, such as small-molecule drugs.

The proposal is part of implementing the Comprehensive Outbound Investment National Security (aka COINS) Act, which passed in December 2025. The rule also forbids U.S. companies from building or expanding their own operations in China to engage in those activities—though drugmakers would still be free to strike licensing deals for molecules.

The biopharma industry has more questions than answers at this stage, though many are concerned the rule could limit the future of dealmaking between the U.S. and Chinese sectors. BIO President and CEO John F. Crowley put it succinctly in a statement: “The details of the proposed Treasury Department rules matter. We cannot restrict our way to success.”

The U.S. action was not the first volley between the two nations. Earlier this month, China proposed tighter export controls on five advanced biomedical technologies, including tech related to cell and gene therapies. China’s proposal also exempted licensing deals, which reached 81 transactions worth up to $110 billion in the first half of 2026.

– Andrew Wishon, Editor-in-Chief

Employer Coverage Costs Keep Climbing, KFF Survey Finds

KFF last week published its 2026 Employer Health Benefits Survey, and with nearly 157 million Americans under 65 relying on employer-sponsored insurance, the findings matter. The 28th annual survey of more than 1,900 employers offers the most detailed picture of such coverage.

The headline: workers are paying more. The average worker contribution for family coverage rose 9% to $7,471, or $621 more than in 2025—outpacing the 6% and 7% increases of recent years. Total family premiums, including the employer’s share, average $28,303, up 5%. Wages grew 3.7% and inflation 2.7%.

So far, employers have absorbed most of the increase, covering nearly three-quarters of the bill. However, in media coverage, KFF survey author Matthew Rae noted that the jump in costs may signal that employers are reaching a tipping point that could shift costs further to workers.

What’s driving the trend? The overall cost of healthcare keeps climbing, and premiums follow. Prescription drugs are another pressure point. Only 18% of large firms cover GLP-1 drugs for weight loss, down from last year. Yet 29% of those that do say the drugs have significantly affected drug spending.

Employers are turning to a range of strategies to keep costs down, including switching insurers or administrators, adding prior authorization, moving to narrow networks and offering lower-cost mail-order generics.

The survey results land during the countdown to a midterm election characterized in large part by affordability challenges. About 7 in 10 registered voters call healthcare “one of the most important issues” in an October NORC poll.

– Megan Hickey, Managing Director

FDA, CMS Preview Changes to Widen Access to Gene Therapies

For patients with rare genetic diseases, a therapy may need to be tailored to a mutation shared by only a handful of people—or even a single patient. On October 27, the FDA and CMS took steps to make developing and accessing such treatments more feasible.

The FDA issued draft guidance designed to address a longstanding challenge for individualized genome-editing therapies. Rather than requiring developers to pursue a separate approval every time a therapy is adapted for a different mutation, the framework would allow certain variants targeting the same gene to fall under a single Biologics License Application. Later in the process, new patient-specific versions that stay within predefined boundaries can be added through a supplement, potentially clearing a significant hurdle to developing treatments for very small patient populations.

As the FDA works to make these therapies more practical to develop, CMS is looking at what happens once they reach patients. The agency plans to expand its Cell and Gene Therapy Access Model beyond sickle cell disease, opening it to therapies for other rare diseases and certain cancers. CMS will invite more manufacturers to participate in outcomes-based agreements with Medicaid programs, with negotiations able to begin close to FDA approval.

– Stephen Tellone, Associate Director

Circled on Our Calendar
Quotes of the Week
  • “Today’s regulatory pathways were designed for drugs that are identical and for devices and tests that perform the same function for every patient. Forcing personalized vaccines into a traditional drug pathway has consequences” – Karen E. Knudsen and Othman Laraki, STAT
  • “Put simply, when a physician, caregiver, policymaker or congressional staffer asks ChatGPT or Gemini about a new therapy, the answer is increasingly built from independent news coverage, not corporate messaging” – Jamie Shearer, MM+M
  • “When premiums spike and millions lose coverage, it is easy to blame insurers, hospital monopolies or drugmakers. They bear plenty of responsibility. But the deeper failure is structural: Our health insurance model is an artifact of an era when medicine didn’t actually work very well” – Michael Botta, The Hill
Other News
See you next week …
–  Real Chemistry
 
Know a friend or colleague that would enjoy the Value Report?
Invite them to sign up here.
© Real Chemistry, All Rights Reserved.